Reviva Pharmaceuticals Holdings Inc (RVPH)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.34-10.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · RVPH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
RVPH — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-05-13
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer of Listing. As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the “Company”) was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market (“Nasdaq”) and the Company had until May 11, 2026, which was the maximum extent of t…
Why it matters: Reviva reported $19.9 million in cash at June 30, 2026, but RECOVER-2 enrollment needs more funding. A sharp cash drop may add pressure to the trial plan.
Worry ifA later filing reports cash below $19.9 million and no new funding for RECOVER-2.
Less concerning ifA later filing reports cash of at least $19.9 million, or new funding that covers RECOVER-2 enrollment.
Why it matters: FDA support could let Reviva use the new form in RECOVER-2 and its planned NDA. That change is tied to a patent-life goal through 2046.
Watch forReviva reports FDA feedback in Q4 2026 that supports using the new form in RECOVER-2 and the planned NDA.
Also watch forReviva reports that the FDA does not support the new form for RECOVER-2 or the planned NDA.
Why it matters: A granted patent could protect brilaroxazine for longer. The company filed an application, but no grant has been reported.
Supportive ifThe U.S. patent office grants a patent for the new-form brilaroxazine composition. The stated protection lasts through 2046.
Worry ifThe patent office rejects the application, or the granted claims do not cover the new form through 2046.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$453 on $10,000 · ±4.5% | How much price usually moves either way. |
| Bad day | $1,343 loss on $10,000 · 13.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,772 loss on $10,000 · 97.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.